Stockreport

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Eyenovia, Inc.  (EYEN) 
Last eyenovia, inc. earnings: 3/25 04:05 pm Check Earnings Report
PDF Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) [Read more]